OBJECTIVES: To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. RESULTS: The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression.
Prostate cancer; Systems pathology; Wnt/β-catenin pathway
Puig P, Erill N, Terricabras M, Subirana I, González-García J, Asensi-Puig A, et al. Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer. BMC Res Notes. 2019;12(1):68.
Use this identifier for quote and/or link this documenthttp://hdl.handle.net/11351/3835
This item appears in following collections
The following license files are associated with this item: